UCLB spinout MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa. This technology derives from research undertaken at the UCL Institute of Ophthalmology, London
emmaadmin2020-03-03T10:07:02+00:00• PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR • AAV-RPGR is the only XLRP treatment in development to be awarded P [...]